I have been selling down based on the slow (at least IMO) revenues to date. Agree that there should be a re-rate on US approval but unless sales accelerate there will be another 6-9 months of waiting. I’d rather re-invest these days when it’s approved. The slow steady progress is fine for staff and board but it’s an opportunity cost for retail holders. Also see the uptake of new technology doesn’t always happen in the medical field as many are set in their ways. It will take some push from OCC to accelerate uptake. Safe hold but there may be better opportunities. GLTA
I have been selling down based on the slow (at least IMO)...
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $78.59M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 37.5¢ | $9.877K | 26.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9729 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 19292 | 4 |
View Market Depth
| Last trade - 11.26am 02/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |